2026-04-14T02:22:14Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2041232024-11-29T10:35:00Zcom_2072_1057col_2072_478917col_2072_478921

00925njm 22002777a 4500 dc Santos Bravo, Marta author Nicolas Plault author Sánchez Palomino, Sonsoles author Rodríguez, Cristina author Navarro Gabriel, Mireia author Mosquera, María Mar author Fernández Avilés, Francesc author Suarez Lledó, María author Rovira, Montserrat author Bodro, Marta author Moreno Camacho, Ma. Asunción author Linares, Laura author Cofán Pujol, Federico author Berengua, Carla author Esteva, Cristina author Cordero, Elisa author Martín Dávila, Pilar author Aranzamendi, Maitane author Pérez Jiménez, Ana Belén author Vidal, Elisa author Fernández Sabé, Núria author Len, Óscar author Hantz, Sebastien author Alain, Sophie author Marcos, Ma. Angeles author the Spanish Network for Research in Infectious Diseases (REIPI) author Group for the Study of Infection in Transplantation (GESITRA) author 2023-12-04T18:21:55Z 2023-12-04T18:21:55Z 2022-11-01 2023-12-04T18:21:55Z Background This study describes the genotypic and phenotypic characterization of novel human cytomegalovirus (HCMV) genetic variants of a cohort of 94 clinically resistant HCMV patients. Methods and results Antiviral-resistant mutations were detected in the UL97, UL54, and UL56 target genes of 25 of 94 (26.6%) patients. The genotype-phenotype correlation study resolved the status of 5 uncharacterized UL54 deoxyribonucleic acid polymerase (G441S, A543V, F460S, R512C, A928T) and 2 UL56 terminase (F345L, P800L) mutations found in clinical isolates. A928T conferred high, triple resistance to ganciclovir, foscarnet, and cidofovir, and A543V had 10-fold reduced susceptibility to cidofovir. Viral growth assays showed G441S, A543V, F345L, and P800L impaired viral growth capacities compared with wild-type AD169 HCMV. Three-dimensional modeling predicted A543V and A928T phenotypes but not R512C, reinforcing the need for individual characterization of mutations by recombinant phenotyping. Conclusions Extending mutation databases is crucial to optimize treatments and to improve the assessment of patients with resistant/refractory HCMV infection. http://hdl.handle.net/2445/204123 Citomegalovirus Resistència als medicaments Cytomegaloviruses Drug resistance Genotypic and phenotypic study of antiviral resistance mutations in refractory cytomegalovirus infection